Dr Hillary Vanderven ~ Lecturer, Immunology/Infectious Disease
Biomedical Sciences and Molecular Biology
- About
-
- Teaching
-
- BM1000: Introductory Biochemistry and Microbiology (Level 1; CNS & TSV)
- BM1001: Introduction to Biomedicine (Level 1; TSV)
- BM1004: Anatomy and Physiology 2 (Level 1; TSV)
- BM3000: Advanced Projects in Biomedicine (Level 3; TSV)
- BM5000: Advanced Projects in Biomedicine (Level 5; TSV)
- MD3011: Introduction to Clinical Healthcare Part 1 of 2 (Level 3; TSV)
- MI3061: Advanced Immunobiology (Level 3; TSV)
- MI5061: Advanced Immunology (Level 5; TSV)
- TV1102: Cell Biology and Biochemistry for Veterinary Science and Agriculture (Level 1; TSV)
- TV2102: Integrated Animal Structure and Function 2 (Level 2; TSV)
- Interests
-
- Research
-
- Immunology
- Influenza virus
- Experience
-
- 2018 to present - Lecturer, Immunology and Infectious Disease, James Cook University (Townsville)
- 2014 to 2018 - PhD in Immunology, University of Melbourne (Melbourne)
- 2012 to 2014 - Biology Laboratory Coordinator, Campus Saint-Jean, University of Alberta (Edmonton)
- 2011 to 2012 - Research Assistant in Transplant Immunology, University of Alberta (Edmonton)
- 2008 to 2011 - M.Sc. in Physiology, Cell and Developmental Biology, University of Alberta (Edmonton)
- 2004 to 2008 - B.Sc. in Biological Sciences with specialisation in Immunology and Infectious Disease, University of Alberta (Edmonton)
- Research Disciplines
- Socio-Economic Objectives
Hillary Vanderven is a lecturer and researcher in the field of Immunology and Infectious Disease at James Cook University in Townsville.
Hillary graduated with a B.Sc. and an M.Sc. specialising in Immunology from the University of Alberta in Edmonton, Canada. She went on to work as a Research Assistant in Transplant Immunology and as a Biology Laboratory Coordinator for undergraduate science students. Hillary moved to Melbourne in 2014, where she completed her PhD under the supervision of Professor Stephen Kent. Her Doctoral thesis focused on characterising the human antibody response to influenza infection, vaccination and immunotherapy.
Hillary's current research investigates the immune system's response to viral and bacterial pathogens, with the aim of improving diagnosis, vaccination and treatment of infectious disease. Her major focus is understanding the immune mechanisms responsible for preventing or controlling influenza virus infections in humans. Primary areas of interest include enhancing influenza vaccine responsiveness in highly susceptible groups (such as older adults) and treating severe influenza with novel antibody-based therapies.
- Honours
-
- Awards
-
- 2017 - Qiagen PhD Achievement Award (Runner-up), University of Melbourne
- 2009 - Alexander Graham Bell Canada Graduate Scholarship (CGS-M), Natural Sciences and Engineering Research Council of Canada (NSERC)
- 2014 to 2018 - International Postgraduate Research Scholarship and Postgraduate Award, University of Melbourne
- Publications
-
These are the most recent publications associated with this author. To see a detailed profile of all publications stored at JCU, visit ResearchOnline@JCU. Hover over Altmetrics badges to see social impact.
- Journal Articles
-
- Vanderven H, Wentworth D, Han W, Peck H, Barr I, Davey R, Beigel J, Dwyer D, Jain M, Angus B, Brandt C, Mykietiuk A, Law M, Neaton J and Kent S (2023) Understanding the treatment benefit of hyperimmune anti-influenza intravenous immunoglobulin (Flu-IVIG) for severe human influenza. JCI Insight, 8 (14).
- Kristensen A, Wragg K, Vanderven H, Lee W, Silvers J, Kent H, Grant M, Kelleher A, Juno J, Kent S and Parsons M (2022) Phenotypic and functional characteristics of highly differentiated CD57 +NKG2C + NK cells in HIV-1- infected individuals. Clinical and Experimental Immunology, 210 (2). pp. 163-174
- Vanderven H, Esterbauer R, Jegaskanda S, Tan H, Wheatley A and Kent S (2022) Poor protective potential of influenza nucleoprotein antibodies despite wide prevalence. Immunology and Cell Biology, 100 (1). pp. 49-60
- Vanderven H and Kent S (2020) The protective potential of Fc‐mediated antibody functions against influenza virus and other viral pathogens. Immunology and Cell Biology, 98. pp. 253-263
- Vanderven H, Barr I, Reynaldi A, Wheatley A, Wines B, Davenport M, Hogarth P and Kent S (2020) Fc functional antibody responses to adjuvanted versus unadjuvanted seasonal influenza vaccination in community-dwelling older adults. Vaccine, 38 (10). pp. 2368-2377
- Bangaru S, Lang S, Schotsaert M, Vanderven H, Zhu X, Kose N, Bombardi R, Finn J, Kent S, Gilchuk P, Gilchuk I, Turner H, García-Sastre A, Li S, Ward A, Wilson I and Crowe J (2019) A site of vulnerability on the influenza virus hemagglutinin head domain trimer interface. Cell, 177 (5). pp. 1136-1152
- Tan H, Esterbauer R, Vanderven H, Juno J, Kent S and Wheatley A (2019) Inducible bronchus-associated lymphoid tissues (iBALT) serve as sites of B cell selection and maturation following influenza infection in mice. Frontiers in Immunology, 10.
- Bangaru S, Zhang H, Gilchuk I, Voss T, Irving R, Gilchuk P, Matta P, Zhu X, Lang S, Nieusma T, Richt J, Albrecht R, Vanderven H, Bombardi R, Kent S, Ward A, Wilson I and Crowe J (2018) A multifunctional human monoclonal neutralizing antibody that targets a unique conserved epitope on influenza HA. Nature Communications, 9. pp. 1-15
- Jegaskanda S, Vanderven H, Tan H, Alcantara S, Wragg K, Parsons M, Chung A, Juno J and Kent S (2018) Influenza infection enhances antibody-mediated NK cell functions via Type I interferon dependent pathways. Journal of Virology, 9 (5).
- Vanderven H, Wragg K, Ana-Sosa-Batiz F, Kristensen A, Jegaskanda S, Wheatley A, Wentworth D, Wines B, Hogarth P, Rockman S, Kent S and INSIGHT FLU005 Pilot Study Writing Group (2018) Anti-influenza hyperimmune immunoglobulin enhances Fc-functional antibody immunity during human influenza infection. Journal of Infectious Diseases, 218 (9). pp. 1383-1393
- Vanderven H, Jegaskanda S, Wines B, Hogarth P, Carmuglia S, Rockman S, Chung A and Kent S (2018) Antibody-dependent cellular cytotoxicity responses to seasonal influenza vaccination in older adults. Journal of Infectious Diseases, 217 (1). pp. 12-23
- Jegaskanda S, Vanderven H, Wheatley A and Kent S (2017) Fc or not Fc; that is the question: antibody Fc-receptor interactions are key to universal influenza vaccine design. Human Vaccines & Immunotherapeutics, 13 (6). pp. 1288-1296
- More
-
ResearchOnline@JCU stores 20+ research outputs authored by Dr Hillary Vanderven from 2012 onwards.
- Current Funding
-
Current and recent Research Funding to JCU is shown by funding source and project.
CUREator - Healthy Security Stream
Generation of novel peptide-MHC antibody therapies to combat seasonal and pandemic potential influenza virus
- Indicative Funding
- $138,920 over 2 years (administered by Myrio Therapeutics Pty Ltd)
- Summary
- Influenza pandemics have caused significant morbidity and mortality throughout history. The 1918 influenza pandemic resulted in 25-50 million deaths globally. Myrio Therapeutics is a Melbourne-based company leading the development of antibodies directed to peptide-MHC (pMHC) targets. Myrio?s competitive edge is provided by a patented Retained Display (ReD) discovery platform allowing rapid isolation of high affinity human single chain antibodies, which are readily converted into different therapeutic formats. Myrio has identified several first-in-class antibodies against highly conserved influenza virus peptides presented on common human leukocyte antigens (HLAs) for further testing in vitro and in vivo in mice.
- Investigators
- Pete Smith, Sinth Jegaskanda, Benjamin Kiefel, Matt Beasley, Lauren Pitt, Hillary Vanderven, Linda Wakim, Daniel Layton and Pouya Faridi (Myrio Therapeutics Pty Ltd, College of Public Health, Medical & Vet Sciences, The University of Melbourne, Commonwealth Scientific & Industrial Research Organisation and Monash University)
- Keywords
- Influenza virus; Antibody-based therapies; Major Histocompatibility Complex; Influenza pandemic preparedness
Myrio Therapeutics Pty Ltd - Contract Research
Assessment of cytotoxicity induced by novel pMHC bi-specific antibodies in vitro
- Indicative Funding
- $11,376 over 1 year
- Summary
- Optimisation and performance of in vitro cell-binding and cytotoxicity assays to assess the capacity of novel bi-specific peptide-MHC (pMHC) antibodies to bind and/or cause killing of peptide-pulsed and influenza-infected cells in vitro.
- Investigators
- Hillary Vanderven (College of Public Health and Medical & Vet Sciences)
- Keywords
- Antibody-based therapies; Influenza virus
The University of New South Wales - Contract Research
The role of non-neutralising ADCC antibodies in the treatment of human influenza B virus (IBV) infection with anti-influenza hyperimmune immunoglobulin (Flu-IVIG)
- Indicative Funding
- $100,000 over 1 year
- Summary
- Antibody-dependent cellular cytotoxicity (ADCC) and other Fc-mediated antibody functions are increasingly recognised as potential mediators of influenza immunity. However, a definitive role for ADCC antibodies during severe human influenza infection remains unclear. The INSIGHT006 study (NCT02287467) provides a unique platform to examine the impact of neutralising and non-neutralising ADCC antibodies, delivered by Flu-IVIG, on outcomes of severe human influenza.
- Investigators
- Hillary Vanderven in collaboration with Stephen Kent (College of Public Health, Medical & Vet Sciences and The University of Melbourne)
- Keywords
- Antibody; Antibody-Dependent Cellular Cytotoxicity; Natural Killer Cells; Antibody Dependent Phagocytosis; Influenza
- Supervision
-
Advisory Accreditation: I can be on your Advisory Panel as a Primary or Secondary Advisor.
These Higher Degree Research projects are either current or by students who have completed their studies within the past 5 years at JCU. Linked titles show theses available within ResearchOnline@JCU.
- Current
-
- Systems serology analysis of Mycobacterium tuberculosis antibody profiles in plasma samples from individuals from Papua New Guinea (Masters , Primary Advisor/AM/Adv)
- Completed
-
- Investigating potential co-factors of Fibropapillomatosis development in Chelonia mydas of the Great Barrier Reef (2021, PhD , Secondary Advisor)
- Collaboration
-
The map shows research collaborations by institution from the past 7 years.
Note: Map points are indicative of the countries or states that institutions are associated with.- 5+ collaborations
- 4 collaborations
- 3 collaborations
- 2 collaborations
- 1 collaboration
- Indicates the Tropics (Torrid Zone)
Connect with me
- Phone
- Location
- Advisory Accreditation
- Primary Advisor
- Find me on…
-
My research areas
Similar to me
-
Prof Andreas LopataBiomedical Sciences and Molecular Biology
-
A/Prof Paul HorwoodVeterinary Science
-
Dr Roland RuscherAustralian Institute of Tropical Health & Medicine
-
Dr Sandip KamathAustralian Institute of Tropical Health & Medicine
-
A/PROF Andreas KupzAustralian Institute of Tropical Health & Medicine